Reported Earlier, Viking Therapeutics Prices $550M Public Offering 6,471,000 Common Shares At $85/Share
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics has announced the pricing of its public offering at $85 per share, aiming to raise $550 million through the sale of 6,471,000 common shares. The proceeds are intended for the development of its VK2809, VK2735, and VK0214 programs, alongside general research, working capital, and corporate purposes.
February 29, 2024 | 8:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics aims to raise $550M through a public offering of 6,471,000 shares at $85 each, funding its VK2809, VK2735, and VK0214 programs.
The successful pricing of Viking Therapeutics' public offering is likely to provide the company with significant capital to advance its drug development programs. This influx of funds is expected to positively impact the company's stock price in the short term, as it demonstrates investor confidence and provides the financial resources needed for its key projects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100